<DOC>
	<DOCNO>NCT01194245</DOCNO>
	<brief_summary>The purpose study compare Humalog ( Insulin lispro ) -recombinant human hyaluronidase ( rHuPH20 ) Novolog ( Insulin aspart ) -rHuPH20 Humalog ( Insulin lispro ) treatment Type 1 Diabetes Mellitus ( T1DM ) basal-bolus therapy .</brief_summary>
	<brief_title>Safety/Efficacy Study Subcutaneously Injected Prandial Insulins Compared Insulin Lispro Alone Participants With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Criteria randomization study include 1 ) fast blood glucose predinner glucose value range 70 140 milligram per deciliter ( mg/dL ) approximately 60 % time 7 day prior randomization 2 ) 90 minute 2-hour postprandial blood glucose &lt; 220 mg/dL approximately 70 % time 7 day prior randomization 3 ) successfully complete 3 day 10-point glucose monitoring least 4 self-monitored blood glucose value non-10-point monitoring day . Participants meet 1 criterion 4- 6-week Titration Period randomize .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Males female age ≥18 year Type 1 Diabetes Mellitus ( T1DM ) treat insulin ≥12 month Body mass index ( BMI ) 18.0 40.0 kilogram per square meter ( kg/m^2 ) . Hemoglobin A1C ( HbA1C ) level 6.7 % 8.2 % , inclusive Fasting Cpeptide &lt; 0.6 nanogram per milliliter ( ng/mL ) Willingness use twice daily ( BID ) insulin glargine basal insulin duration study Willingness avoid use insulin infusion pump unblinded continuous glucose monitoring ( CGM ) study Known suspect allergy component study drug Use pramlintide within 30 day Screening Use drug study within 30 day Screening ( corticosteroid antimetabolite ) could interfere interpretation study result know cause clinically relevant interference insulin action , glucose utilization , recovery hypoglycemia Recurrent severe hypoglycemia ( 2 episode last 6 month ) hypoglycemic unawareness , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Type 1 diabetes</keyword>
</DOC>